Handelsavisen
prelaunch
Companies Healthcare STSS.O
ST
STSS.O NASDAQ Diversified Medical Equipment & Supplies

Sharps Technology Inc

$1,18
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
45,6M USD
P/E
EV / Rev
Div yield
Op margin
ROE
-14,3 %
Net margin
Debt / equity
0,00
Beta
52w range
Volume
Day range
Prev close
$2,00
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Sharps Technology Inc provides medical equipment, supplies, and distribution services within the healthcare sector, primarily generating revenue through the sale and distribution of medical products.

Business. Sharps Technology Inc (STSS.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Sharps Technology is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification99 %
SectorHealth Care
Industry groupDiversified Medical Equipment & Supplies
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
not yet wired
Profitability
-14,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning STSS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to STSS.O. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Sharps Technology Inc (STSS.O) is a healthcare services and equipment company operating within the medical equipment, supplies, and distribution industry. The firm generates revenue primarily through the sale of products, including capital equipment and consumables. Sharps Technology is headquartered in the United States and is listed on the NASDAQ stock exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification99 %
    SectorHealth Care
    Industry groupDiversified Medical Equipment & Supplies
    AI synthesis
    GENERATED

    Sharps Technology Inc has a market capitalization of $77.3 million and a price-to-book ratio of 11.27, indicating a premium valuation relative to its book value. The company has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure. However, its liquidity position is rated as low, and it has a current ratio of 1.15, indicating limited short-term liquidity cushion.

    The company's profitability metrics are negative, with a return on equity of -14.32% and a return on assets of -10.02%. These figures are below the industry norms for medical equipment and supplies firms, which typically exhibit positive returns on equity and assets. The operating and net losses of $1.84 million and $0.98 million, respectively, further underscore the company's unprofitable operations.

    Sharps Technology Inc's revenue is not disclosed in the latest financials, but the most recent actual revenue reported by analysts is $7.01 million. The company does not provide segment or geographic breakdowns in the available data, making it difficult to assess revenue concentration or geographic exposure. Without segment data, it is unclear whether the company is diversified or reliant on a single product line or region.

    The company's growth trajectory is uncertain, as the latest financials show a net loss and negative operating cash flow of $1.89 million. Analysts have not provided forward-looking revenue estimates, and the absence of revenue growth data makes it difficult to project future performance. The company's capital expenditures are minimal, with only $2,850 spent in the latest period, suggesting limited investment in growth or operational expansion.

    Risk factors for Sharps Technology Inc include its unprofitable operations and negative cash flows, which could impact its ability to sustain operations without external financing. The company has no immediate filing-based liquidity or dilution flags, and its dilution risk is rated as low. However, the absence of long-term debt does not eliminate the possibility of future financing needs, which could lead to equity dilution or increased leverage.

    Recent events and filings do not indicate any material changes in the company's operations or financial position. The most recent actual revenue reported by analysts is $7.01 million, but there are no recent earnings calls, transcripts, or 10-K filings provided in the data to assess management commentary or strategic direction.

    Key takeaways
    • Sharps Technology Inc is unprofitable, with a return on equity of -14.32% and a return on assets of -10.02%.
    • The company has a high price-to-book ratio of 11.27, indicating a premium valuation despite negative earnings.
    • Sharps Technology Inc has no long-term debt and a debt-to-equity ratio of 0.0, suggesting a conservative capital structure.
    • The company's liquidity position is rated as low, with a current ratio of 1.15.
    • No immediate filing-based liquidity or dilution flags were detected, and dilution risk is rated as low.
    • The company's growth trajectory is unclear due to the absence of revenue growth data and forward-looking guidance.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Sharps Technology maintains a strong current ratio of 4.02, indicating robust short-term liquidity to meet immediate obligations.

    The company carries minimal leverage with a debt-to-equity ratio of 0.02, reducing financial risk compared to peers.

    Sharps Technology generated gross profit of $6.4 million in fiscal 2026, demonstrating initial revenue generation capability.

    Operating losses improved significantly from fiscal 2024 to 2025, narrowing from $10.1 million to $5.6 million.

    Cash conversion metrics rank in the top quartile relative to the medical equipment cohort median.

    BEAR CASE · 2

    Net income plummeted to a massive loss of $282.5 million in fiscal 2026, signaling severe profitability deterioration.

    Free cash flow turned deeply negative at -$270.2 million in fiscal 2026, indicating significant cash burn.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-03-31
    Q4 2025 · Quarter highlights

    Revenue $4.5M; Operating income −76 271,7% YoY.

    Revenue$4.5M
    Operating income-$162.1M−76 271,7 % YoY
    Net income-$182.7M−3 935,3 % YoY
    Free cash flow-$170.8M−64 443,1 % YoY
    EPS
    Operating cash flow-$16.7M−138,4 % YoY
    Financials
    Income statement
    Revenue$4.5M
    Gross profit$6.4M
    Operating income-$162.1M
    Net income-$182.7M
    Margins
    Gross margin142.0%
    Operating margin-3603.5%
    Net margin-4061.4%
    FCF margin-3797.2%
    Balance sheet
    Total assets$269.1M
    Total liabilities$4.7M
    Total equity$264.4M
    Cash & equivalents
    Long-term debt$3.1M
    Cash flow
    Operating cash flow-$16.7M
    CapEx
    Free cash flow-$170.8M
    SBC
    P&L flow · revenue → net income
    Revenue $4.5MOperating costs $166.6MTax $20.6MNet income $182.7M
    Highlights
    • Revenue $4.5M
    • Operating income −76 271,7% YoY
    • Net income −3 935,3% YoY
    • Free cash flow −64 443,1% YoY
    • Net margin -4061.4%

    Valuation TTM

    Market price
    $1,18
    Market cap
    $77.3M
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    11.3x
    P / Tangible book
    11.3x
    Tangible book
    $6.9M
    Net cash
    Current ratio
    1.1
    Debt / equity
    0.0
    ROA
    -10.0%
    ROE
    -14.3%
    Cash conversion
    192.0%
    CapEx / revenue
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Drug Delivery Systems & Packaging100,0 %
    disclosed · sec_xbrl · 2025-12-31

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryDiversified Medical Equipment & Supplies259,3B node revenueABT 17,1%MDT 14,0%MDLN 11,0%SYK 9,7%BDX 8,4%HSIC 5,1%BAX 4,3%SOLV 3,2%Other 27,2%
    Source: company disclosures · own-taxonomy revenue-covered setSTSS 0,0% · rank #83 of 84

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs STSS · multiples and returns
    AB
    ABT
    Abbott Laboratories
    $107,13
    187,2B USD
    P/E
    26,3x
    vs self
    Div yield
    2,4 %
    vs self
    ROE
    12,5 %
    +26,8 vs self
    MD
    MDT
    Medtronic PLC
    $86,19
    110,3B USD
    P/E
    21,4x
    vs self
    Div yield
    3,4 %
    vs self
    ROE
    9,7 %
    +24,0 vs self
    MD
    MDLN
    MEDLINE INC.
    $40,47
    53,2B USD
    P/E
    202,6x
    vs self
    Div yield
    vs self
    ROE
    vs self
    SY
    SYK
    Stryker Corp
    $341,20
    131,8B USD
    P/E
    38,0x
    vs self
    Div yield
    vs self
    ROE
    13,5 %
    +27,8 vs self
    BD
    BDX
    Becton Dickinson And Co
    $170,21
    48,4B USD
    P/E
    25,6x
    vs self
    Div yield
    2,8 %
    vs self
    ROE
    7,0 %
    +21,3 vs self
    HS
    HSIC
    Henry Schein Inc
    $88,21
    10,1B USD
    P/E
    80,5x
    vs self
    Div yield
    vs self
    ROE
    3,0 %
    +17,3 vs self
    BA
    BAX
    Baxter International Inc
    $28,10
    14,5B USD
    P/E
    vs self
    Div yield
    2,3 %
    vs self
    ROE
    -15,4 %
    -1,1 vs self
    SO
    SOLV
    SOLVENTUM CORPORATION
    $76,83
    13,3B USD
    P/E
    8,6x
    vs self
    Div yield
    vs self
    ROE
    30,8 %
    +45,1 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    ROE-14,3 %Below median
    D/E0,00Above median
    Cash Conv1,92Above median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Return On Equity
      net_income / total_equity
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    Source documents
    • Sharps Technology Inc Market data — financials · 2026-05-29
    • Sharps Technology Inc Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    588.4Kshares short-1.2% vs prior
    1.97days to cover
    742fails-to-deliver
    as of 2026-05-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    STSS.OCanonical
    NASDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Gross margin (FY 2025-12-31): -202.5%Derived (calculated)
    • Return on equity (FY 2025-12-31): -106.9%Derived (calculated)
    • Return on assets (FY 2025-12-31): -105.0%Derived (calculated)
    • Current ratio (FY 2025-12-31): 4.02xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 0.02xDerived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -62.6%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): -11.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -149.7%Derived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 3,579.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 13,144.6%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 1,275.6%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): -4,744.7%Derived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): 99.5%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): 99.5%Derived (calculated)
    • Net margin (FY 2025-12-31): -138,400.0%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -2,938.9%Derived (calculated)
    • Total assets (annual): USD 269.08MSEC XBRL filing
    • Cost of revenue (annual): USD 617.45KSEC XBRL filing
    • Pre-tax income (annual): USD -270.34MSEC XBRL filing
    • EPS (diluted) (annual): USD-PER-SHARES -11SEC XBRL filing
    • R&D expense (annual): USD 198.76KSEC XBRL filing
    • Gross profit (annual): USD -413.32KSEC XBRL filing
    • Cash & equivalents (annual): USD 10.38MSEC XBRL filing
    • Shareholders' equity (annual): USD 264.38MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-03-31 16:48 UTCEARNINGSQuarterly results — Q4 2025 Revenue USD 4.5M · Net USD -182.7M
    2026-03-31 16:48 UTCEARNINGSAnnual results — FY 2026 Revenue USD 7.0M · Net USD -282.5M
    2025-08-13 17:23 UTCEARNINGSQuarterly results — Q2 2025 Revenue USD 0.2M · Net USD 3.6M
    2025-03-27 17:31 UTCEARNINGSQuarterly results — Q4 2024 Revenue USD 0.0M · Net USD -4.5M
    2025-03-27 17:31 UTCEARNINGSAnnual results — FY 2025 Revenue USD 0.0M · Net USD -9.3M
    2024-11-14 15:17 UTCEARNINGSQuarterly results — Q3 2024 Revenue USD 0.0M · Net USD -1.7M
    2024-08-14 16:45 UTCEARNINGSQuarterly results — Q2 2024 Revenue USD 0.0M · Net USD -2.1M
    2024-05-14 16:23 UTCEARNINGSQuarterly results — Q1 2024 Revenue USD 0.0M · Net USD -1.0M
    2024-03-29 15:30 UTCEARNINGSAnnual results — FY 2024 Revenue USD 0.0M · Net USD -9.8M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage